MENU
简体中文
ENG
Home
About Us
Our Facilities
SPIRO Site
PINE Site
OBiO Intelli-M
Leadership Team
Laboratory Sciences
CDMO Solutions
Process Development
cGMP Manufacturing
Viral Vector
Oncolytic Virus
Cell Therapy Products
Plasmid & Nucleotides
Quality & Regulatory
Cold Chain Logistics
Innovations
Insights
Press Releases
Events
Knowledge Center
Investor Relations
Contact Us
Enable Gene Therapy For Better Lives
Your Trustful Partner in Research and Manufacturing for Gene and Cell Therapy
Make Gene Delivery Accessible
Side-by-Side Navigation for Your Innovations
Industrialize Your Product At OBiO
End-to-End Offerings with Versatile Technical Platform
In China For Global Customers
OBiO Intelli-M with a 77,000 sqm GMP footprint will start operating in late 2022
Providing client-centered and high-quality service as our commitment, we strive to become a world leading gene and cell therapy CRO/CDMO group.
Our Offering
CDMO
Solutions
OBiO offers holistic solutions in process development, analytical method, IND-enabling CMC, clinical and commercial contract manufacturing of viral vector, oncolytic virus, and cell therapy products.
Laboratory
Sciences
OBiO provides an integrated portfolio of plasmid construction, viral packaging, cell biology and animal study services for biomedical researchers.
Our Facilities
SPIRO Site
Integrated Laboratory Services
Process and Analytical Method Development
Research and Development Center
International Medical Park Shanghai, China
OBiO Intelli-M
Process Development & Characterization
Clinical and Commercial Manufacturing
77,000-square-meter Facility for Global Supply
Lin-Gang Free-Trade Zone Shanghai, China
PINE Site
Process and Analytical Method Development
Pre-clinical and Clinical Manufacturing
Three-building, 10,000-square-meter campus
International Medical Park Shanghai, China
Insights
Press Releases
Events
May 13,2022
OBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual Meeting
OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', SSE:688238.SH), today announced that research on novel manufacturing technologies via its OVersatile™ platform will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual meeting on May 16-19, 2022 in Washington, D.C.
Mar 22,2022
OBiO Technology Goes Public on Shanghai Stock Exchange Today
SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology (Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238).
May 11,2021
OBiO Announces ASGCT 24th Annual Meeting Attendance
OBiO Biotechnology (Shanghai) Corp. Ltd., (“OBiO” or “the Company”), announced it will be attending the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting to be held virtually from May 11-14, 2021.
ALL PRESS RELEASES
APR 15-16, 2022
SAPA-GP 2022 Annual Conference (Hybrid)
King of Prussia, PA
MAY 16-19, 2022
ASGCT 25TH ANNUAL MEETING
WASHINGTON, D.C.
JUL 15-16, 2022
China Oncolytic Virus Conference 2022 (Hybrid)
SHANGHAI, China
ALL EVENTS
Contact Us
First Name*
Last Name*
Company*
Email*
Phone Number*
I'm interested in…
Please choose
General Inquiry
Laboratory Sciences
Process Development
Analytical/Formulation Development
Non-IND (IIT) Service
IND-Enabling CMC (IND-CMC) Service
Clinical Manufacturing
Commercial Manufacturing
Extended Services (Pre-IND/Post-IND)
Investor Relations
Questions or Comments
Security Code*
I AGREE*
By submitting this form I agree that OBiO may process my data in the manner described in OBiO’s
Privacy Policy
We won’t share your information.
Main
+86 400-151-5198
For General Inquiry
oobio@obiosh.com
For Business Inquiry
bd@obiosh.com
About Us
Laboratory Services
Insights
Innovations
Investor Relations
CDMO Solutions
Process Development
cGMP Manufacturing
Quality & Regulatory
Cold Chain Logistics
Privacy Policy
© 2022 OBiO Technology (Shanghai) Corp., Ltd. All Rights Reserved
